Middle East: Antisera Market 2024

Antisera Market Size in the Middle East

After four years of growth, the Middle Eastern antisera market decreased by -40% to $X in 2021. The total consumption indicated tangible growth from 2012 to 2021: its value increased at an average annual rate of +2.3% over the last nine-year period. The trend pattern, however, indicated some noticeable fluctuations being recorded throughout the analyzed period. Over the period under review, the market reached the maximum level at $X in 2020, and then reduced remarkably in the following year.

Antisera Production in the Middle East

In value terms, antisera production soared to $X in 2021 estimated in export price. In general, production recorded a significant decrease. The most prominent rate of growth was recorded in 2019 with an increase of 334% against the previous year. The level of production peaked at $X in 2017; however, from 2018 to 2021, production stood at a somewhat lower figure.

Antisera Exports

Exports in the Middle East

In 2021, the amount of antisera and other blood fractions exported in the Middle East soared to X tons, with an increase of 61% against 2020. In general, exports showed significant growth. The most prominent rate of growth was recorded in 2014 when exports increased by 124% against the previous year. The volume of export peaked in 2021 and is expected to retain growth in years to come.

In value terms, antisera exports expanded markedly to $X in 2021. Overall, exports enjoyed a significant expansion. The most prominent rate of growth was recorded in 2014 when exports increased by 75%. The level of export peaked in 2021 and is likely to see gradual growth in years to come.

Exports by Country

Turkey dominates exports structure, accounting for X tons, which was approx. 90% of total exports in 2021. It was distantly followed by Iran (X tons), mixing up a 4.6% share of total exports. Israel (X tons) held a minor share of total exports.

Turkey was also the fastest-growing in terms of the antisera and other blood fractions exports, with a CAGR of +43.1% from 2012 to 2021. At the same time, Iran (+8.6%) displayed positive paces of growth. By contrast, Israel (-9.0%) illustrated a downward trend over the same period. From 2012 to 2021, the share of Turkey increased by +63 percentage points.

In value terms, Turkey ($X) remains the largest antisera supplier in the Middle East, comprising 74% of total exports. The second position in the ranking was taken by Israel ($X), with a 15% share of total exports.

In Turkey, antisera exports increased at an average annual rate of +71.9% over the period from 2012-2021. The remaining exporting countries recorded the following average annual rates of exports growth: Israel (+4.5% per year) and Iran (+4.2% per year).

Export Prices by Country

In 2021, the export price in the Middle East amounted to $X per ton, with a decrease of -30.2% against the previous year. Over the period under review, the export price recorded a relatively flat trend pattern. The most prominent rate of growth was recorded in 2020 an increase of 26%. As a result, the export price reached the peak level of $X per ton, and then dropped notably in the following year.

Prices varied noticeably country of origin: the country with the highest price was Israel ($X per ton), while Turkey ($X per ton) was amongst the lowest.

From 2012 to 2021, the most notable rate of growth in terms of prices was attained by Turkey (+20.1%), while the other leaders experienced mixed trends in the export price figures.

Antisera Imports

Imports in the Middle East

After nine years of growth, purchases abroad of antisera and other blood fractions decreased by -9.2% to X tons in 2021. Overall, imports, however, saw a prominent expansion. The most prominent rate of growth was recorded in 2014 with an increase of 26% against the previous year. Over the period under review, imports hit record highs at X tons in 2020, and then reduced in the following year.

In value terms, antisera imports soared to $X in 2021. Over the period under review, imports, however, enjoyed a buoyant increase. The growth pace was the most rapid in 2014 with an increase of 29% against the previous year. The level of import peaked in 2021 and is likely to continue growth in the near future.

Imports by Country

In 2021, Turkey (X tons), distantly followed by Israel (X tons), Saudi Arabia (X tons), Iraq (X tons), Lebanon (X tons), Iran (X tons) and the United Arab Emirates (X tons) represented the largest importers of antisera and other blood fractions, together comprising 87% of total imports.

From 2012 to 2021, the most notable rate of growth in terms of purchases, amongst the main importing countries, was attained by Saudi Arabia (with a CAGR of +30.3%), while imports for the other leaders experienced more modest paces of growth.

In value terms, Turkey ($X) constitutes the largest market for imported antisera and other blood fractions in the Middle East, comprising 39% of total imports. The second position in the ranking was taken by Israel ($X), with a 17% share of total imports. It was followed by Saudi Arabia, with a 12% share.

In Turkey, antisera imports expanded at an average annual rate of +14.8% over the period from 2012-2021. The remaining importing countries recorded the following average annual rates of imports growth: Israel (+26.0% per year) and Saudi Arabia (+36.5% per year).

Import Prices by Country

The import price in the Middle East stood at $X per ton in 2021, rising by 28% against the previous year. Over the period from 2012 to 2021, it increased at an average annual rate of +5.2%. As a result, import price reached the peak level and is likely to continue growth in the immediate term.

Average prices varied somewhat amongst the major importing countries. In 2021, major importing countries recorded the following prices: in Turkey ($X per ton) and the United Arab Emirates ($X per ton), while Iraq ($X per ton) and Iran ($X per ton) were amongst the lowest.

From 2012 to 2021, the most notable rate of growth in terms of prices was attained by Iraq (+12.2%), while the other leaders experienced more modest paces of growth.

Source: IndexBox Platform

Frequently Asked Questions (FAQ) :